支持痴呆患者独立生活的新心理社会干预(NIDUS-family)对家庭照护者及居家痴呆患者的临床与成本效果:一项随机对照试验
该试验计划纳入297对痴呆患者-家庭照护者组合,按2:1随机分为NIDUS-family干预联合常规照护组(n=199)或单纯常规照护组(n=98),主要结局为12个月时家庭照护者评定的目标达成量表(GAS)评分,并评估12个月成本效果。NIDUS-family是首个可个性化定制、由非临床培训引导员实施的手册化干预。
要点
- NIDUS-family是首个可针对痴呆患者及其家庭个人目标定制、由非临床培训引导员实施的手册化干预。
- 试验采用随机、两臂、单盲、多中心设计,计划纳入297对痴呆患者-家庭照护者组合。
- 主要结局为12个月时家庭照护者评定的目标达成量表(GAS)评分,并评估12个月成本效果。
核心结论
- 将评估NIDUS-family联合常规照护与单纯常规照护相比,在12个月随访时对家庭照护者评定的目标达成量表(GAS)评分的影响,并确定NIDUS-family联合常规照护是否比单纯常规照护在12个月内更具成本效果。
研究设计与样本
- 随机、两臂、单盲、多中心临床试验,涉及297对痴呆患者-家庭照护者组合。
- 组合按2:1随机分配至NIDUS-family干预联合常规照护组(n=199)或单纯常规照护组(n=98)。
主要发现
- 干预组在1年内接受干预:初始6个月内通过6-8次视频通话或电话会话(若招募期COVID-19限制允许则面对面)进行,随后每1-2个月电话随访以支持实施,由受训引导员提供。
- NIDUS-family利用行为管理、照护者支持、心理教育、沟通与应对技能训练、赋能及环境调整等组件,模块根据组合所选目标选择。
关键数值与推荐
- 主要结局为12个月随访时由家庭照护者评定的目标达成量表(GAS)评分。
- 成本效果评估时间为12个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most people living with dementia want to remain living in their own homes and are supported to do so by family carers. No interventions have consistently demonstrated improvements to people with dementia's life quality, functioning, or other indices of living as well as possible with dementia. We have co-produced, with health and social care professionals and family carers of people with dementia, a new intervention (NIDUS-family). To our knowledge, NIDUS-family is the first manualised intervention that can be tailored to personal goals of people living with dementia and their families and is delivered by facilitators without clinical training. The intervention utilizes components of behavioural management, carer support, psychoeducation, communication and coping skills training, enablement, and environmental adaptations, with modules selected to address dyads' selected goals. We will evaluate the effect of NIDUS-family and usual care on goal attainment, as measured by Goal Attainment Scaling (GAS) rated by family carers, compared to usual care alone at 12-month follow-up. We will also determine whether NIDUS-family and usual care is more cost-effective than usual care alone over 12 months. METHODS: A randomised, two-arm, single-masked, multi-site clinical trial involving 297 people living with dementia-family carer dyads. Dyads will be randomised 2:1 to receive the NIDUS-family intervention with usual care (n = 199) or usual care alone (n = 98). The intervention group will be offered, over 1 year, via 6-8 video call or telephone sessions (or face to face if COVID-19 restrictions allow in the recruitment period) in the initial 6 months, followed by telephone follow-ups every 1-2 months to support implementation, with a trained facilitator. DISCUSSION: Increasing the time lived at home by people living with dementia is likely to benefit lives now and in the future. Our intervention, which we adapted to include remote delivery prior to trial commencement due to the COVID-19 pandemic, aims to address barriers to living as well and as independently as possible that distress people living with dementia, exacerbate family carer(s) stress, negatively affect relationships, lead to safety risks, and frequently precipitate avoidable moves to a care home. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number ISRCTN11425138 . Registered on 7 October 2019.
引用
- Burton A, Rapaport P, Palomo M, et al. Clinical and cost-effectiveness of a New psychosocial intervention to support Independence in Dementia (NIDUS-family) for family carers and people living with dementia in their own homes: a randomised controlled trial. Trials. 2021. PMID: 34857029. doi:10.1186/s13063-021-05851-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。